Objective: Thrombocytopenia occurs at 7% of pregnant women. Along with other causes, idiopathic thrombocytopenic purpura (ITP) which is an autoimmune disease with autoantibodies causing platelet destruction must be considered in differential diagnosis. Antiplatelet antibodies can cross the plasenta and cause thrombocytopenia at newborn. Aim of our study is to assess management of ITP in pregnancy, and to investigate neonatal outcomes. Material and Methods: This retrospective study was conducted in a tertiary center including 89 pregnant patients with ITP followed between October 2011 and January 2018. Patients were evaluated in two groups due to diagnosis of ITP and chronic ITP. Age, obstetric history, ITP diagnose and follow up period, presence of splenectomy, platelet count during pregnancy and after birth, treatment during pregnancy, route of delivery, weight and platelet count of newborn, sign of hemorrhage, and fetal congenital anomaly were assessed. Results: Considering ITP and chronic ITP groups, no significant difference was seen with respect to parity, timing of delivery, preoperative and postoperative platelet counts and hemoglobin values. Route of delivery, birth weight, APGAR scores, newborn platelet count, and congenital anomaly rates were also similar. Timing of treatment were different as patiens whose diagnosis were established during pregnancy were mostly treated for preparation of delivery. Treatment modalities were similar. Conclusion: Probability of severe thrombocytopenia at delivery is higher in ITP patients who were diagnosed during pregnancy when compared to patients who got prepregnancy diagnosis. ITP is an important disease for both mother and newborn. Patients should be followed closely in cooperation with hematology department.
Introduction
Thrombocytopenia which is defined as platelet count being less than 150x10 3 /μL, occurs at approximately 7% of pregnant women (1) . Various etiologies can cause thrombocytopenia during pregnancy. Most commonly seen gestational thrombocytopenia and idiopathic thrombocytopenic purpura (ITP) are both diagnosis of exclusion of other pathologies necessitating different treatment strategies. These pathologies include preeclampsia, HELLP syndrome characterized by hemolysis, elevated liver enzymes and low platelet count, sepsis, disseminated intravascular coagulation, autoimmune diseases such as systemic lupus eritematosus, thrombotic thrombocytopenic purpura, microangiopathies like hemolytic uremic syndrome, hematologic malignancies, and drug induced thrombocytopenias (2, 3, 4) . Gestational thrombocytopenia, which usually occurs at mid-second to third trimester and which is a mild form with platelet counts more than 70x10 3 /μL, constitutes 70-80% of cases (1, 5) . ITP, which is an autoimmune disease with autoantibodies against platelet membrane causing platelet destruction in reticuloendothelial system, must be considered in differential diagnosis. ITP incidence at pregnancy is 1-2 at 1000 and it forms 3-5% of thrombocytopenias encountered during pregnancy, though it is the most common cause of thrombocytopenias in early pregnancy and it can cause severe thrombocytopenia (2, 5, 6) . Patients may be asymptomatic, or may have antenatal bleeding necessitating treatment. Thrombocytopenia may firstly be diagnosed during pregnancy or ITP diagnose may have been established before pregnancy. ITP lasting more than 6 months is called chronic ITP (1). Splenectomy may be performed due to resistance to treatment. Time of diagnose, severity and accompanying other factors must be considered for differential diagnosis of thrombocytopenia. Beginning time of ITP can U n c o r r e c t e d P r o o f affect pregnancy and delivery complications, and clinical situations of newborn such as thrombocytopenia, petechia and intracranial hemorrhage (1) . Aim of our study is to assess follow up and treatment of ITP and chronic ITP during pregnancy, along with neonatal outcomes. Proper diagnoses and management in antenatal period will reduce complications.
Materials and Methods
This retrospective study was conducted at a university hospital, including pregnant patients with ITP. A total of 89 patients followed between October 2011 and January 2018 in our center with ICD diagnose codes of pregnancy Z33, Z34.8, Z35.8, Z35.9 and concurrently D69.3 ITP code or D69.6 thrombocytopenia code were included. Records of patients were investigated, and phone calls with patients were used for missing data. Other causes of thrombocytopenia were excluded. Age, obstetric and medical history, time of ITP diagnose and follow up period, presence of splenectomy, platelet counts in early and late pregnancy and after birth, complete blood count and biochemistry parameters, treatment during pregnancy, route of delivery and anesthesia, need for thrombocyte or erythrocyte replacement, gestational week at time of birth, weight, APGAR scores and platelet count of newborn, sign of fetal hemorrhage and fetal congenital anomaly were assessed. SPSS 23.0 program was used for statistical analysis. Categorical measurements were assessed as number and percent, continious measurements were summarized as mean and standard deviation. Chi square or Fisher test statistics were used to compare categorical variables. To compare continious variables between groups, ranges were assessed, one way variance analysis Anova or Student t test in dual groups for variables in parametric range were used. p<0.05 was considered significant for all tests. This study was approved by Institutional Review Board and Ethics Commitee.
Results
Mean age of 89 patients included in the study was 30, mean age of ITP diagnosis was 28. Mean gestational week at birth was 37 weeks and 5 days, mean birth weight was 3073 g, mean hemoglobin preoperatively and postoperatively were 11.7 g/dL and 10.4 g/dL respectively. Mean platelet count of patients was 98x10 3 /μL, ranging between 19 x10 3 /μL and 622 x10 3 /μL. Mean platelet count of newborns was 226x10 3 /μL. Mean parity of patients was 2. Chronic ITP was diagnosed at 36% of patients. Time of diagnosis was in first trimester at 11% of patients, in second trimester at 18% of patients, in third trimester at 34% of patients. Smoking women constituted 6.7%. Cesarean operation was performed for 75% of patients due to previous cesarean or other obstetrical indications, and 11% these patients were applied neuroaxial anesthesia. Antenatal bleeding was not encountered at 84.3% of patients, while 10.3% had vaginal bleeding and 4.3% had bleeding of other sites which was not related to pregnancy. Of all patients, 42.7% necessitated treatment, 28.9% of which was for delivery preparation. Treatment was administered in third trimester at 44.7% of cases, and 26.3% was applied in first or second trimester. Treatment modality was steroid for 12.4% of patients, while platelet transfusion for 9.0%, steroid and platelet transfusion for 7.9%, steroid and platelet transfusion and intravenous immunglobulin (IVIG) for 13.5% of patients were applied. No treatment was needed for 57.3% of the patients. Erythrocyte transfusion beyond other treatments was administered at 11 patients. Splenectomy had been performed at 5(5.6%) patients. Of 89 pregnancies, one resulted in missed abortus, one resulted in termination of pregnancy, one ended with intrauterine exitus at 26 th week, and delivery data of 5 patients could not be reached due to delivery at other centers. Data of 81 newborns were assesed. Neonatal intensive care unit admission was needed for 19.7% of newborns. Of 81 newborn babies, 7 (8.6%) had thrombocytopenia. Babies who did not have thrombocytopenia in the first examination were not controlled again in terms of platelet count. Babies with platelet count <30x10 3 /μL were hospitalized and their platelet count were controlled daily, while platelet counts >50 x10 3 /μL were checked every 2-3 days. When patients were classified in two groups as ITP and chronic ITP, 57 patients were diagnosed in ITP group and 32 patients were diagnosed in chronic ITP group. No significant difference was seen between two groups with respect to parity, timing of delivery, birth weight, preoperative and postoperative platelet counts and hemoglobin values, newborn platelet counts, 1 st and 5 th minute APGAR scores, and newborn intensive care unit admission. Time of diagnosis were significantly different between two groups, mean age being 30.3 for ITP patients and 23.8 for chronic ITP patients (p < 0.001) ( Table 1 ). Smoking rate was significantly higher in chronic ITP group (p=0.001). Route of delivery, antenatal bleeding and congenital anomaly rates were similar. There were 3 congenital anomalies leading to neonatal death in chronic ITP group; aort coarctation -ventricular septal defect -patent ductus arteriosus -pulmonary HT in the first baby, transposition of great arteries in the second baby, and patent ductus arteriosus in the third baby. The latter baby had also thrombocytopenia, and had intraventricular and subdural hemorrhage. None of other babies had intracranial hemorrhage. In the ITP group, one pregnancy was terminated due to severe skeleton deformity, one baby had hydroureteronephrosis, and two babies had hypospadias. Furthermore, one pregnancy was resulted in intrauterin exitus at 26 th week in ITP group, and there was one missed abortus in chronic ITP group.
U n c o r r e c t e d P r o o f
Of all patients, low platelet counts were found at 7 of the newborn babies, 4 of whom were in ITP group with platelet count between 51-66 x10 3 /μL, while 3 babies whose platelet count were <30x10 3 /μL were in chronic ITP group. These babies underwent transfontanel and abdominal ultrasound imaging, and no hemorrhage was found except the above mentioned baby who had patent ductus arteriosus. Timing of treatment were different between groups (p=0.034) ( Table 2) . Patiens whose diagnosis were established during pregnancy were mostly treated for preparation of delivery. Treatment modalities were similar (Table 3 ). Erythrocyte transfusion rates were also similar. All patients who had splenectomy were in the chronic ITP group, and they had splenectomy operation before or after pregnancy, therefore, none of our patients necessitated such operation for treatment during pregnancy. Discussion Differential diagnosis of thrombocytopenia in pregnancy may be difficult. Beginning time of thrombocytopenia, its severity and relationship with other abnormal clinical conditions direct the diagnose. Especially gestational thrombocytopenia and ITP diagnosed after second trimester of pregnancy may be difficult to differentiate. However, ITP causes more severe thrombocytopenia and it may necessitate treatment in the beginning of pregnancy or in proceeding weeks. Steroid and IVIG are most commonly used treatments. However, timing of treatment may affect potential side effects. Steroids which are used as first step treatment, may cause fetal anomalia when used in early pregnancy. Furthermore, it must be kept in mind that steroids may increase complications such as hypertension, gestational diabetes, and premature labor (2) . When thrombocyte response to steroids is insufficient or the side effects are intolerable, IVIG treatment can be used alone or in combination with low dose steroids (4). Sun et al., who compared effectiveness of steroid and IVIG treatments in their retrospective study with 235 pregnant patients, did not find significant difference between groups with respect to maternal platelet count and newborn results (7) . Wang et al. also declared similar treatment efficacy (3). Other drugs like mycophenolate mophetyl, immunsupressants such as azathioprine, and thrombopoietin receptor agonists can also be used for treatment (4, 8) . Treatment choice is decided due to efficacy, toxicity and cost of the drugs. In our study, 57.3% of the patients did not need treatment, 30.3% were given platelet transfusion alone or in combination with other treatments. ITP and chronic ITP groups were similar with respect to all treatment modalities used. Platelet transfusion is mostly effective in emergency cases when there is little time to wait for the consequences of other treatments. Gernsheimer et al., reported 5-18.9% platelet transfusion rates before delivery in ITP patients (4) . Some of our patients were followed in other hospitals and were canalized for delivery to our hospital as a tertiary center. This situation can explain higher rates of platelet transfusion when compared to previous studies. Resistance to treatment or severe toxicity may necessitate splenectomy for remission of the patient. This operation is allowed to be performed in the second trimester, however, it is emphasized that transplasental crossing of maternal antibodies and risk of neonatal thrombocytopenia is not affected by splenectomy (4) . Though, none of our patients necessitated splenectomy for treatment during pregnancy. Wysznski et al. conducted a study with 446 pregnant patients with ITP, and they concluded that fetal demise, premature delivery, and congenital anomalia risk were higher in patients diagnosed as ITP or chronic ITP before pregnancy when compared to patiens diagnosed during pregnancy, and maternal ITP duration affected pregnancy significantly, however, other medical conditions of mother and the medications used were not mentioned and their effects could not be evaluated (1). Subbaiah et al., in their study with 30 pregnancies of 26 patients with ITP, did not find increased rates of preterm delivery, low birth weight, still birth or neonatal death in pregnancies of ITP patients, besides, they did not report significant difference between the platelet count in early pregnancy and before delivery (2) . Of our patients, 64% were new diagnosed in pregnancy, and 36% had chronic ITP. When we compared these two groups, gestational week at delivery, birth weight, and congenital anomalies were similar. Also, in Subbaiah's study, probability of severe thrombocytopenia at delivery was shown to be higher in ITP patients diagnosed during pregnancy when compared with patients who got diagnose before pregnancy (2) . Difference in treatment time in our study is consistent with this result. As stated previosly, route of delivery as normal vaginal birth or cesarean section does not affect hemorrhagic complications in ITP patients, and the decision must be led due to obstetrical indications (5, 6) . Gernsheimer et al. reported that treatment would usually not be necessary in the absence of bleeding symptoms or when the number of platelets were >30x10 3 /μL in pregnant women with ITP (4). Won et al also suggested that the number of platelets of mother should be >30x10 3 /μL during pregnancy and >50x10 3 /μL near delivery, furthermore more than 50x10 3 /μL platelets for normal vaginal birth or cesarean section, and more than 80x10 3 /μL platelets for neuroaxial anesthesia was requested. It was emphasized that for asymptomatic patients treatment might not be necessary until delivery if the platelet count was above 20x10 3 /μL, however these patients should be followed closely (6) . Lee et al also stated little risk of epidural hematom related to neuroaxial anesthesia for platelet count >70x10 3 /μL (9) . In our own clinical practice, neuroaxial anesthesia is prefered for patients with platelet numbers above 100x10 3 /μL. Besides, in our center, suggestion of hematology department is mostly close monitoring of platelet count and follow up without treatment as long as platelet count is >30x10 3 /μL and the patient is asymptomatic.
Steroid treatment is recommended in case of decline in platelet count and when the patient is symptomatic, >70x10 3 /μL platelet is suggested for delivery, and close follow up of the newborn in terms of immune thrombocytopenia is recommended. Also, platelet count must be evaluated with peripheral blood smear before treatment. Antiplatelet antibodies can cross the placenta and cause thrombocytopenia at newborn. Wounds on face and scalp, petechies, cleft palate, intraventricular hemorrhagia and hydrocephalus, cardiac anomalies such as atrial septal defect, ventricular septal defect and patent ductus arteriosus may be seen at newborn. Preterm labour or low birth weight may be encountered both in patients with ITP and chronic ITP. Maternal ITP which is resistant to splenectomy was reported to be related to higher rates of intracranial hemorrhage at newborn (1). Furthermore, it was shown in several studies that maternal platelet count at delivery was not related to platelet count of newborn and maternal treatment did not affect newborn platelet count. It was emphasized that risk factors for neonatal thrombocytopenia were maternal history of splenectomy, maternal platelet count less than 50x10 3 /μL in pregnancy, and neonatal thrombocytopenia in previous pregnancies of mother (3, 5) . Among our patients, there were 7 newborns with thrombocytopenia, and platelet counts were < 50x10 3 /μL at 3 of the mothers in this subgroup, besides, one of the mothers had splenectomy, therefore, these numbers may not be sufficient to draw a conclusion on risk factors of neonatal thrombocytopenia. Fujimura et al. reported neonatal thrombocytopenia as 9-15%, however, denoted that risk of fetal intracranial hemorrhagia was very low (10). Loustau et al., reported 8.3 % severe thrombocytopenia without hemorrhagic complication in newborn (11) . Neonatal thrombocytopenia rate was 8.6% in our study, and we did not find significant difference between ITP and chronic ITP groups in this aspect. Gernsheimer reported that neonatal platelet count was not needed to be repeated if it was normal in the first examination. However, for newborns with thrombocytopenia, thrombocyte count should be checked daily and cranial ultrasound should be performed when platelet count is <50000 (4). Our practice is consistent with these implementations.
Limitations of our study are its retrospective nature and the missing data. Obstetric records of the referred patients were based on patient anamnesis. Also some of the patients were admitted to other centers for delivery which led to incomplete newborn data. In conclusion, ITP diagnosed before or during pregnancy is important for both mother and newborn. Though, risk of severe thrombocytopenia at delivery is higher in ITP when compared to chronic ITP. Patients should be followed closely at a tertiary center in cooperation with hematology department. Probability of hemorrhage during pregnancy, and preparation for either normal vaginal birth or cesarean section must all be considered and platelet count must be kept stable. Newborn platelet count must also be closely followed in terms of immune thrombocytopenia.
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